Phencyclidine- and dizocilpine-induced hyperlocomotion are differentially mediated

Neuropsychopharmacology

Volumn 11, Issue 3, 1994, Pages 167-177

  Ögren, Sven Ove ^a   Goldstein, Menek ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

DA d2 receptors; Dizocilpine; Glutamate; Haloperidol; Nmda receptors; Phencyclidine; Raclopride; Remoxipride

Indexed keywords

DIZOCILPINE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENCYCLIDINE; QUINPIROLE; RACLOPRIDE; RECEPTOR SUBTYPE; REMOXIPRIDE;

ANIMAL EXPERIMENT; ARTICLE; CATALEPSY; CONTROLLED STUDY; HYPERACTIVITY; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

ANALYSIS OF VARIANCE; ANIMAL; DIZOCILPINE MALEATE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; ERGOLINES; HALOPERIDOL; MALE; MOTOR ACTIVITY; PHENCYCLIDINE; QUINPIROLE; RACLOPRIDE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; REMOXIPRIDE; SALICYLAMIDES;

EID: 0028054345     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/sj.npp.1380103     Document Type: Article

References (68)

1. Carboni E, Imperato A, Perezzain L, DiChiara G (1989): Amphetamine, cocaine, phencyclidine and nomifensine increase extra-cellular dopamine concentrations preferentially in the nucleus accumbens of freely moving rats. Neuroscience 28:653-661
2. Carlson JH, Bergstrom DA, Walters JR (1987): Stimulation of both Di and D2 dopamine receptors appears necessary for full expression of postsynaptic effects of dopamine agonists: A neurophysiological study. Brain Res 400: 205-218
3. Carlsson M, Carlsson A (1989): The NMDA antagonist MK- 801 causes marked locomotor stimulation in monoamine- depleted mice. J Neural Transm 75:221-226
4. Chapman CD, Gazarra RA, Howard SG (1990): Effects of phencyclidine on extracellular levels of dopamine, di- hydroxyphenylacetic acid and homovanillic acid in conscious and anesthetized rats. Neuropharmacology 29:319-325
5. Christensen AV, Amt J, Hyttel J, Larsen JJ, Svendsen O (1984): Pharmacological effects of a specific dopamine Di an tagonist SCH 23390 in comparison with neuroleptics. Life Sci 34:1529-1540
6. Clineschmidt BV, Martin GE, Bunting PR (1982): Anticonvulsant activity of (+)-5-methyl-10, ll-dihydro-5H-di- benzo[a, d]cyclohepten-5-10-imine (MK-801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties. Drug Dev Rev 8:135-145
7. Contreras PC, Rice KC, Jacobson AE, O'Donohue TL (1986): Stereotyped behaviour correlates better than ataxia with phencyclidine-receptor interactions. Eur J Pharmacol 121:9-18
8. Daly SA, Waddington JL (1993): Behavioural effects of the putative D3 dopamine receptor agonist 7-OH-DPAT in relation to other "Dz-like" agonists. Neuropharmacology 32:509-510
9. Deutch AY, Tam S-Y, Freeman AS, Bowers MB, Roth RH (1987): Mesolimbic and mesocortical dopamine activation induced by phencyclidine: Contrasting pattern to striatal responses. Eur J Pharmacol 134:257-264
10. Deutch SI, Mastropaolo J, Schwartz BL, Rosse RB, Morihisa JM (1989): A "glutamatergic hypothesis" of schizophrenia. Clin Neuropharmacol 12:1-13
11. Ford LM, Norman AB, Sanberg PR (1989): The topography of MK-801-induced locomotor patterns in rats. Physiol Behav 46:755-758
12. Freeman AS, Bunney BS (1984): The effects of phencyclidine and N-allylnormetazocine on midbrain dopamine neuronal activity. Eur J Pharmacol 104:287-293
13. French ED, Vantini G (1984): Phencyclidine-induced locomotor activity in the rat is blocked by 6-hydroxy-dopamine lesion of the nucleus accumbens: Comparisons to other psychomotor stimulants. Psychopharmacology 82:83-88
14. French ED, Ceci A (1990): Non-competitive N-methyl-D- aspartate antagonists are potent activators of ventral tegmental A10 dopamine neurons. NeurosciLett 19:159-162
15. French ED, Pilapil C, Quirion R (1985): Phencyclidine binding sites in the nucleus accumbens and phencyclidine- induced hyperactivity are decreased following lesions of the mesolimbic dopamine system. Eur J Pharmacol 116: 1-9
16. French ED, Ferkany J, Abreu M, Levenson S (1991): Effects of competitive N-methyl-D-aspartate antagonists on mid- brain dopamine neurons: An electrophysiological and behavioural comparison to phencyclidine. Neuropharmacology 30:1039-1046
17. Gasic GP, Hollmann M (1992): Molecular neurobiology of glutamate receptors. Annu Rev Physiol 54:507-536
18. Goodwin P, Starr BS, Starr MS (1992): Motor responses to dopamine Di and D2 agonists in the reserpine-treated mouse are affected differentially by the NMDA receptor antagonist MK 801. J. Neural Transm 4:15-26
19. Hall H, Sallemark M, Jerning E (1986): Effects of remoxipride and some related new substituted salicylamides on rat brain receptors. Acta Pharmacol Toxicol 58:61-70
20. Hiramatsu M, Cho AK, Nabeshima T (1989): Comparison of the behavioral and biochemical effects of the NMDA receptor antagonists, MK-801 and phencyclidine. Eur J Pharmacol 166:359-366
21. Hoffman DC (1992): Typical and atypical neuroleptics an tagonize MK-801-induced locomotion and stereotypy in rats. J Neural Transm 89:1-10
22. Hollander M, Wolfe DA (1973): Nonparametric statistical methods. Wiley, New York.
23. Hyttel J (1978): Effects of neuroleptics on 3H-haloperidol and 3H-cis(Z)-flupenthixol binding and adenylate cyclase activity in vitro. Life Sci 23:551-556
24. Imperato A, Scrocco MG, Bacchi S, Angelucci L (1990): NMDA receptors and in vivo dopamine release in the nucleus accumbens and caudatus. Eur J Pharmacol 187:555-556
25. Javitt DC, Zukin SR (1991): Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148: 1301-1308
26. Johnston KM (1987): Phencyclidine: behavioural and biochemical evidence supporting a role for dopamine. Fed Proc 42:2579-2583
27. Johnston KM, Jones SM (1990): Neuropharmacology of phencyclidine: Basic mechanisms and therapeutic potential. Annu Rev Pharmacol Toxicol 30:707-750
28. Kashihara K, Hamamura T, Okumura K, Otsuki S (1990): Effect of MK-801 on endogenous dopamine release in vivo. Brain Res 528:80-82
29. Kim JS, Kornhuber HH, Schmid-Burgk W, Holzmuller B: Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett 20:379-382
30. Koek W, Woods JH, Winger GD (1988): MK-801, a proposed non-competitive antagonist of excitatory amino acid neurotransmission, produces phencyclidine-like behavioural effects in pigeons, rats and rhesus monkeys. J Pharmacol Exp Ther 245:969-974
31. Kohler C, Hall H, Ogren SO, Gawell L (1985): Specific in vitro and in vivo binding of 3H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D2 receptors in the rat brain. Biochem Pharmacol 34: 2251-2259
32. Kohler C, Radesater AC, Karlsson-Boethius G, Bryske B, Wid- man M (1992): Regional distribution and in vivo binding of the atypical antipsychotic drug remoxipride. A biochemical and autoradiographic analysis in the rat brain. J Neural Transm 87:49-62
33. Levesque D, Diaz J, Pilon C, Martres MP, Giros B, Souil E, Schott D, Morgat JL, Schwartz JC, Sokoloff P (1992): Identification, characterization, and localization of the dopamine D3 receptor in rat brain using 7-[3H]hydroxy- N, N, -di-n-propyl-2-aminotetralin. Proc Natl Acad Sci USA 89:8155-8159
34. Liljequist S, Ossowska K, Grabowska-Anden M, Anden N-E: Effect of the NMDA receptor antagonist, MK-801, on locomotor activity and on the metabolism of dopamine in various brain areas of mice. Eur J Pharmacol 195:55-61
35. Lillrank SM, O'Connor WO, Ungerstedt U (1991): The effects of phencyclidine on neurotransmitter release from the dorsolateral striatum of awake moving rats. In Rollema H, WesterinkBHC, Drijthout WJ (eds), Monitoring molecules in neuroscience, Noordwijkerhout, Proceedings of 5th International Conference on in vivo methods. Sept. 21-24, The Netherlands, pp 98-101
36. Lodge D, Davies SN, Jones MG, Miller J, Mannalack DT, Orn- stein PL, Verberne AJM, Young N, Beart PM (1988): A comparison of the in vitro and in vivo activity of five potent and competitive NMDA antagonists. BrJ Pharmacol 95:957-965
37. Loscher W, Annies R, Hdnack D (1991): The N-methyl-D- aspartate receptor antagonist MK-801 induces increases in dopamine and serotonin metabolism in several brain regions of rats. Neurosci Lett 128:191-194
38. Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelley R (1959): Study of a new schizophrenomimetic drug— Sernyl. Arch Neurol Psychiatry 81:363-369
39. Martin GE (1986): Catecholamine release within the striatum of the freely moving rat. Ann NY Acad Sci 473:151-159
40. McKinney WT (1989): Animal models of schizophrenic disorders. In Schulz SC, Tamminga CA (eds), Schizophrenia: Scientific Progress, Oxford University Press, New York, pp 141-154
41. Mohell NA, Sallemark M, Rosqvist S, Malmberg AH, Jack- son DM (1993): Binding characteristics of remoxipride and its metabolites to dopamine D2 and D3 receptors. Eur J Pharmacol 238:121-125
42. Monaghan DT, Bridges RJ, Cotman CW (1989): The exitatory amino acid receptors: their classes, pharmacology, and distinct properties in the function of the central nervous system. Annu Rev Pharmacol Toxicol 29:365-401
43. Morari M, O'Connor WT, Ungerstedt U, Fuxe K (1993): N-methyl-D-aspartic acid differentially regulates extracellular dopamine, GABA and glutamate levels in the dorsolateral striatum of the halothane-anaesthetized rat: An in vivo microdialysis study. J Neurochem 60:1884-1895
44. Murase S, Mathe JM, Grenhoff J, SvenssonTH(1993): Effects of dizocilpine (MK-801) on rat midbrain dopamine cell activity: Differential actions on bring pattern related to anatomical localization. J Neural Transm 91:13-25
45. Ogren SO, Kohler C, Fuxe K, Angeby K (1979): Behavioural effects of ergot drugs. In Fuxe K, Caine DB (eds), Dopamine ergot derivatives and motor function. Oxford, Per- gamon Press, pp 187-205
46. Ogren SO, Hall H, Kohler C, Magnusson O, Lindbom L-O, Angeby K, Florvall L (1984): Remoxipride, a new potential antipsychotic compound with selective anti- dopaminergic actions in the rat brain. Eur J Pharmacol 102:459-474
47. Ogren SO, Hall H, Kohler C, Magnusson O, Sjostrand SE (1986): The selective dopamine D2 receptor antagonist raclopride discriminates between dopamine-mediated motor functions. Psychopharmacology 90:287-294
48. Ogren SO, Florvall L, Hall H, Magnusson O, Angeby-Moller K (1990): Neuropharmacological and behavioural properties of remoxipride in the rat. Acta Psychiatr Scand 82 (Suppl. 358) 82:21-26
49. Ogren SO, Thyreen G, Lindeberg A, Amkeus E (1994a): Remoxipride and other dopamine receptor antagonists in two tests of catalepsy in the rat. Comparison with dopamine receptor functions in the striatum. Psychopharmacology. Submitted.
50. Ogren SO, Rosen L, Fuxe K (1994b): The dopamine D2 antagonist remoxipride acts in vivo on a subpopulation of dopamine D2 receptors. Neuroscience 61:269-283
51. Ouagazzal A, Nieoullon A, Amalric M (1993): Effects of dopamine Di and D2 receptor blockade on MK-801-induced hyperlocomotion in rats. Nauyn-Schmideberg's Arch Psychopharmacology 111:427-434
52. Pawlowski L, Mathe JM, Svensson TH (1990): Phencyclidine activates rat A10 dopamine neurons but reduces burst activity and causes regularization of firing. Acta Physiol Scand 139(3):529-530
53. Raffa RB, Ortegon ME, Robisch DM, Martin GE (1989): In vivo demonstration of the enhancement of MK-801 by L-glu- tamate. Life Sci 44:1593-1599
54. Rao TS, Kim HS, Lehmann J, Martin LL, Wood PL (1990): Selective activation of dopaminergic pathways in the mesocortex by compounds that act at the phencyclidine (PCP) binding site: Tentative evidence for PCP recognition sites not coupled to N-methyl-D-aspartate (NMDA) receptors. Neuropharmacology 29:225-230
55. Reid AA, Mattson MV, de Costa BR, Thurkauf A, Jacobson AE, Monn JA, Rice KC, Rothmann RB (1990): Specificity of phencyclidine binding sites in guinea pig brain. Neuropharmacology 29:811-817
56. See RE, Sorg BA, Chapman MA, Kalivas PW (1991): In vivo assessment of release and metabolism of dopamine in the ventrolateral striatum of awake rats following administration of dopamine Di and D2 receptor agonists and antagonists. Neuropharmacology 30:1269-1274
57. Snell LD, Mueller ZL, Gannon RL, Silvermann B, Johnson K (1984): A comparison between classes of drugs having phencyclidine like behavioral properties on dopamine efflux in vitro and dopamine metabolism in vivo. J Pharmacol Exp Ther 231:261-269
58. Sokoloff P, Andrieux M, Besancon R, Pilon C, Martres MP, Giros B, Schwarts JC (1992): Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: Comparison with D2 receptor. Eur J Pharmacol 225:331-337
59. Stahle L (1992): Do autoreceptors mediate dopamine agonist induced yawning and suppression of exploration? A critical review. Psychopharmacology 106:1-13
60. Sturgeon RD, Fessler RG, Meltzer HY (1979): Behavioural rating scales for assessing phencyclidine-induced locomotor activity, stereotyped behaviour and ataxia in rats. Eur J Pharmacol 59:169-179
61. Tiedtke PI, Bischoff C, Schmidt WJ (1990): MK-801-induced stereotypy and its antagonism by neuroleptic drugs. J Neural Transm 81:173-182
62. Titus RD, Kornfeld EC, Jones ND, Clemens JA, Smalstig EB, Fuller RW, Hahn RA, Hynes MD, Mason NR, Wong DT, Foreman MM (1983): Resolution and absolute configuration of an ergolene-related dopamine agonist, trans- 4, 4a, 5, 6, 7, 8, 8a, 9-octahydro-5-propyl-H(or 2H)-pyrazolo- [3, 4-g]-quinoline. J Med Chem 26:1112-1116
63. Tricklebank MD, Singh L, Oles RJ, Preston C, Iversen SD (1989): The behavioural effects of MK-801: a comparison with antagonists acting non-competitively and competitively at the NMD A receptor. Eur J Pharmacol 167:127-135
64. Tsuruta K, Frey EA, Grewe CW, Cote TE, Eskay RL, Keba- bian JW (1981): Evidence that LY-141865 specifically stimulates the D2 dopamine receptor. Nature 292:463- 465
65. Werling LL, Jacocks III HM, McMahon PN (1990): Regulation of [3H] dopamine release from guinea pig striatum by NMDA receptor/channel activators and inhibitors. J Pharmacol Exper Ther 255:40-45
66. Willets J, Balster RL, Leander D (1990): The behavioral pharmacology of NMDA receptor antagonists. Trends Pharmacol Sci 11:423-428
67. Wong EHF, Kemp JA (1991) Sites for antagonism on the N-methyl-D-aspartate receptor channel complex. Ann Rev Pharmacol Toxicol 31:401-425
68. Wong EHF, Kemp JA, Priestly T, Knight AR, Woodruff GN, Iversen LL (1986): The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist. Proc Natl Acad Sci USA 83:7104-7108